Friday, June 22, 2012

Alzheimer's: Bapineuzumab and Solanezumab

Survey shows dim faith in Lilly, Pfizer Alzheimer's drugs
Ransdell Pierson | Reuters
The Chicago Tribune
June 19, 2012


"Results from the survey of 146 investors were released late on Tuesday by Mark Schoenebaum, a pharmaceutical analyst for the investment research services group. Wall Street is eagerly awaiting results of the trials and expects huge potential sales if either of the medicines proves able to arrest the progression of the memory-robbing disease.

"Pfizer and Lilly are expected in the third quarter to disclose the main findings from large studies of their respective medicines, bapineuzumab and solanezumab. Complete data are expected to be presented at medical meetings in the fourth quarter.

"The survey responders, on average, gave solanezumab only a 14 percent chance of meeting all the primary goals of its two Phase III studies, compared with an average 21 percent probability for the two big trials of bapineuzumab, Schoenebaum said."


Read the full article

Comments by the Pharmalot blog on this report, from the 20th of June:

Read the blog entry from Pharmalot.

No comments: